Wedge Capital Management L L P NC Invests $31.61 Million in Halozyme Therapeutics, Inc. $HALO

Wedge Capital Management L L P NC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 403,824 shares of the biopharmaceutical company’s stock, valued at approximately $31,607,000. Wedge Capital Management L L P NC owned about 0.34% of Halozyme Therapeutics as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Mizuho Markets Americas LLC lifted its position in Halozyme Therapeutics by 270.8% in the 4th quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after buying an additional 926,526 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Halozyme Therapeutics by 19,326.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 85,476 shares of the biopharmaceutical company’s stock worth $5,753,000 after buying an additional 85,036 shares in the last quarter. Hussman Strategic Advisors Inc. grew its position in Halozyme Therapeutics by 66.7% during the fourth quarter. Hussman Strategic Advisors Inc. now owns 52,500 shares of the biopharmaceutical company’s stock valued at $3,533,000 after acquiring an additional 21,000 shares during the last quarter. Assetmark Inc. raised its stake in shares of Halozyme Therapeutics by 11.9% during the fourth quarter. Assetmark Inc. now owns 137,415 shares of the biopharmaceutical company’s stock worth $9,248,000 after acquiring an additional 14,568 shares in the last quarter. Finally, Asset Management One Co. Ltd. raised its stake in shares of Halozyme Therapeutics by 1,358.0% during the fourth quarter. Asset Management One Co. Ltd. now owns 24,844 shares of the biopharmaceutical company’s stock worth $1,713,000 after acquiring an additional 23,140 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

HALO has been the subject of a number of recent research reports. Citizens Jmp boosted their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Morgan Stanley lowered their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday. UBS Group restated a “buy” rating and set a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, HC Wainwright raised their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $51,886,572.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 44,103 shares of company stock valued at $3,142,896 over the last three months. Corporate insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $102.62 on Wednesday. The firm has a market capitalization of $11.65 billion, a price-to-earnings ratio of 30.63, a PEG ratio of 0.43 and a beta of 0.85. The stock has a fifty day moving average of $77.89 and a 200 day moving average of $71.92. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $104.78. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the business earned $1.54 EPS. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.